Navigation Links
Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
Date:6/23/2009

protect against human infection from anthrax. In studies conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Restanza was shown to be highly active in vitro against 30 strains of anthrax. In May 2007, a non-human primate study showed that a 30-day course of oral Restanza was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, but the FDA has not yet approved the drug for marketing in this or any other indication.

In addition to its development in anthrax, Restanza is also being developed to combat other high priority bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis) under a two year, $3.8 million contract with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense.

FDA's "Animal Efficacy Rule" and the Use of Non-Human Primates

The "Animal Efficacy Rule" allows for approval of new drug products based on animal data when adequate and well-controlled efficacy studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers. Approval of a drug under the "Animal Efficacy Rule" is subject to certain post-approval commitments, including the submission of a plan for conducting post-marketing studies, post-marketing restrictions to ensure safe use (if deemed necessary), and product labeling information intended for patient advising that, among other things, indicates the product's approval was based on efficacy studies conducted in animals alone.

The non-human primates use
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Global Stem Cells Group ... Bioquark, Inc.’s biologic products for the regeneration and repair of ... Global Stem Cells Group’s ambitious expansion plans in Latin America, ... access to regenerative medicine and stem cell therapies. , ... biologics that have the ability to alter the regulatory state ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced ... Product , Test, Application & End User - Forecast ... The bioburden testing market is expected to reach $565.6 ... at a CAGR of 9.8% from 2014 to 2019 ... testing market is segmented into consumables and instruments. The ...
(Date:6/2/2015)... Jun. 02, 2015 Tauriga Sciences, Inc. (OTCQB:  ... sciences company with interests in the natural wellness ... platform technology, today announced that it has officially ... ("Typenex") in exchange for a one-time cash payment ... Company and Typenex entered into a Settlement Agreement ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... the "Molecular Diagnostics - Global Market Size, Strategy ... their offering. "Molecular Diagnostics - Global Market ... data that analysts and planners can use. Hundreds of ... 2015 United States Medicare Fee Payment Schedules to help ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3
... early signal of transport of key amyloid ... CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") ... drug,RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, ... trial found that treatment with RVX-208,resulted in a ...
... (OTC,Bulletin Board: GOVX) ("GeoVax" or "the Company"), a ... HIV-1 (Human,Immunodeficiency Virus) and other infectious agents, today ... an operational update., Robert McNally, GeoVax,s President ... progress we,ve made during the third quarter of ...
... RAPIDS, Mich., Nov. 10 The West Michigan ... the incorporation,and financing of a new medical device ... West Michigan Science & Technology offices in,Grand Valley ... will work to develop and commercialize novel surgical ...
Cached Biology Technology:RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 2GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 3GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 4GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 5GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 6GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 7GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 8GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 9West Michigan's Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures 2
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... the National Human Genome Research Institute (NHGRI), part of ... has identified six more genetic variants involved in type ... genetic risk factors associated with increased risk of the ... new study had previously been suspected of playing a ...
... tiny gaps across which information crosses between nerve cells. ... play a vital role in both memory formation and ... Assistant professor Josh Dubnau, Ph.D., leads a ... fruit flies, or Drosophila. His team had previously identified ...
... shark populations worldwide are declining from destructive high-seas commercial ... products (mainly fins and meat), with some shark populations ... according to a comprehensive new book co-edited by shark ... www.pewoceanscience.org ), published by Blackwell Publishing, and being released ...
Cached Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists identify a mechanism that helps fruit flies lock-in memories 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 2Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 3Oceanic sharks worldwide at serious risk from high-seas fishing, rising demand for shark products 4
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... 2/3D Waver Shaker combines shaking and rocking for ... 330 x 330 mm stainless steel or acrylic ... and cold room operation. The platform angle is ... a vigorous with action and rotation speed of ...
... kit for 25 chips provides the chips ... analysis (at picogram levels) with the Experion ... RNA HighSens microfluidic chips, 2 x 1,250 ... RNA HighSens stain, 20 microliters RNA ladder, ...
... complete SSCP kit provides all the accessories ... by single-stranded conformation polymorphism analysis (SSCP) with ... kit includes a cooling finger adaptor for ... 2 sets of 20 cm plates, 2 ...
Biology Products: